Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8.
Adaptor Proteins, Signal Transducing
/ genetics
Adenocarcinoma
/ genetics
Carcinoma, Pancreatic Ductal
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
Humans
Male
MicroRNAs
/ genetics
Neoplasm Invasiveness
/ genetics
Neoplasm Proteins
/ genetics
Prognosis
Sequence Analysis, RNA
Journal
Journal of human genetics
ISSN: 1435-232X
Titre abrégé: J Hum Genet
Pays: England
ID NLM: 9808008
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
03
01
2019
accepted:
07
02
2019
revised:
07
02
2019
pubmed:
13
3
2019
medline:
5
9
2019
entrez:
13
3
2019
Statut:
ppublish
Résumé
Our ongoing analyses identifying dysregulated microRNAs (miRNAs) and their controlled target RNAs have shed light on novel oncogenic pathways in pancreatic ductal adenocarcinoma (PDAC). The PDAC miRNA signature obtained by RNA sequencing showed that both strands of pre-miR-130b (miR-130b-5p, the passenger strand and miR-130b-3p, the guide strand) were significantly downregulated in cancer tissues. Our functional assays revealed that miR-130b-5p significantly blocked the malignant abilities of PDAC cell lines (PANC-1 and SW1990), e.g., cancer cell proliferation, migration, and invasion. A total of 103 genes were identified as possible oncogenic targets by miR-130b-5p regulation in PDAC cells based on genome-wide gene expression analysis and in silico database search. Among the possible targets, high expression of 9 genes (EPS8, ZWINT, SMC4, LDHA, GJB2, ZCCHC24, TOP2A, ANLN, and ADCY3) predicted a significantly poorer prognosis of PDAC patients (5-year overall survival, p < 0.001). Furthermore, we focused on EPS8 because its expression had the greatest impact on patient prognosis (overall survival, p < 0.0001). Overexpression of EPS8 was detected in PDAC clinical specimens. Knockdown assays with siEPS8 showed that its overexpression enhanced cancer cell proliferation, migration, and invasion. Analysis of downstream RNA networks regulated by EPS8 indicated that MET, HMGA2, FERMT1, RARRES3, PTK2, MAD2L1, and FLI1 were closely involved in PDAC pathogenesis. Genes regulated by antitumor miR-130b-5p were closely involved in PDAC molecular pathogenesis. Our approach, discovery of antitumor miRNAs and their target RNAs, will contribute to exploring the causes of this malignant disease.
Identifiants
pubmed: 30858505
doi: 10.1038/s10038-019-0584-6
pii: 10.1038/s10038-019-0584-6
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
EPS8 protein, human
0
MIRN130 microRNA, human
0
MicroRNAs
0
Neoplasm Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-534Références
Curr Pharm Des. 2015;21(10):1249-55
pubmed: 25506899
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
J Hum Genet. 2017 Nov;62(11):935-944
pubmed: 28659612
Leuk Res. 2015 Jun;39(6):575-81
pubmed: 25843487
Crit Rev Eukaryot Gene Expr. 2010;20(2):141-8
pubmed: 21133843
Cancer Res. 2010 Dec 1;70(23):9979-90
pubmed: 21118970
Oncotarget. 2017 Jul 26;8(41):70097-70115
pubmed: 29050264
Int J Oncol. 2015 Jan;46(1):205-14
pubmed: 25333707
Cancer Sci. 2018 Sep;109(9):2919-2936
pubmed: 29968393
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Oncogene. 2013 Jul 4;32(27):3286-95
pubmed: 22847613
Br J Cancer. 2017 Jul 25;117(3):409-420
pubmed: 28641312
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Mol Oncol. 2019 Feb;13(2):322-337
pubmed: 30444038
Mol Med Rep. 2016 Oct;14(4):3220-8
pubmed: 27573546
J Hum Genet. 2017 Jul;62(7):671-678
pubmed: 28275243
Gynecol Oncol. 2012 Feb;124(2):325-34
pubmed: 22005523
Elife. 2015 Jul 11;4:e08314
pubmed: 26163656
Cancer Metastasis Rev. 2017 Sep;36(3):525-545
pubmed: 28836104
Eur Rev Med Pharmacol Sci. 2015;19(5):825-34
pubmed: 25807437
J Hum Genet. 2018 Dec;63(12):1197-1210
pubmed: 30228364
EMBO J. 1993 Oct;12(10):3799-808
pubmed: 8404850
J Biol Chem. 2007 Jul 6;282(27):19399-409
pubmed: 17496330
Cancer Sci. 2017 Jan;108(1):124-135
pubmed: 27862697
Cell Biochem Funct. 2018 Jun;36(4):194-202
pubmed: 29653464
Oncotarget. 2017 May 2;8(18):30288-30304
pubmed: 28415821
PLoS One. 2014 Feb 10;9(2):e84311
pubmed: 24520312
Cancer Sci. 2018 Apr;109(4):1239-1253
pubmed: 29417701
Oncotarget. 2018 Jun 22;9(48):28849-28865
pubmed: 29988949
Oncotarget. 2017 May 29;8(32):53180-53193
pubmed: 28881803
J Hum Genet. 2017 Jan;62(1):33-40
pubmed: 27251005
PLoS One. 2013 Sep 10;8(9):e73803
pubmed: 24040078
J Mol Endocrinol. 2014 Mar 06;52(2):181-9
pubmed: 24443580
BMC Cancer. 2015 Jan 31;15:29
pubmed: 25637514
J Hematol Oncol. 2017 Feb 6;10(1):43
pubmed: 28166834
J Hum Genet. 2018 May;63(5):657-668
pubmed: 29540855
J Cancer. 2016 Jul 07;7(11):1497-514
pubmed: 27471566
Cancer Sci. 2018 Jun;109(6):2013-2026
pubmed: 29660218
Int J Urol. 2018 Nov;25(11):953-965
pubmed: 30153702
Int J Urol. 2015 Mar;22(3):242-52
pubmed: 25599923
Front Plant Sci. 2017 Dec 22;8:2200
pubmed: 29312425
Sci Rep. 2016 Feb 03;6:20574
pubmed: 26837847